ATE386034T1 - Pyrazoloisoquinolinenderivaten als kinase inhibitoren - Google Patents
Pyrazoloisoquinolinenderivaten als kinase inhibitorenInfo
- Publication number
- ATE386034T1 ATE386034T1 AT03742433T AT03742433T ATE386034T1 AT E386034 T1 ATE386034 T1 AT E386034T1 AT 03742433 T AT03742433 T AT 03742433T AT 03742433 T AT03742433 T AT 03742433T AT E386034 T1 ATE386034 T1 AT E386034T1
- Authority
- AT
- Austria
- Prior art keywords
- kinase inhibitors
- pyrazoloisoquinoline derivatives
- pyrazoloisoquinoline
- derivatives
- nik
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2003/021144 WO2005012301A1 (en) | 2003-07-03 | 2003-07-03 | Pyrazoloisoquinoline derivatives as kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE386034T1 true ATE386034T1 (de) | 2008-03-15 |
Family
ID=34114817
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03742433T ATE386034T1 (de) | 2003-07-03 | 2003-07-03 | Pyrazoloisoquinolinenderivaten als kinase inhibitoren |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1644371B1 (de) |
JP (1) | JP2007521227A (de) |
CN (1) | CN1802373A (de) |
AT (1) | ATE386034T1 (de) |
AU (1) | AU2003304380A1 (de) |
BR (1) | BR0318383A (de) |
CA (1) | CA2531291A1 (de) |
DE (1) | DE60319158T2 (de) |
IL (1) | IL172942A0 (de) |
MX (1) | MXPA05013485A (de) |
WO (1) | WO2005012301A1 (de) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR058223A1 (es) * | 2005-11-25 | 2008-01-23 | Palau Pharma Sa | Un comuesto de derivados de pirazoloisoquinolina, un procedimiento para l a preparacion de dicho compuesto y una composicion farmaceutica que comprende dicho compuesto |
WO2007106884A2 (en) | 2006-03-15 | 2007-09-20 | Theralogics, Inc. | Methods of treating muscular wasting diseases using nf-kb activation inhibitors |
FR2944792B1 (fr) * | 2009-04-24 | 2011-05-20 | Sanofi Aventis | Derives de 1h-pyrazolo[4,3-c]isoquinoleines, leur preparation et leur application en therapeutique |
CN101955480B (zh) * | 2010-01-28 | 2012-07-04 | 新乡医学院 | 一种吡唑并[3,4-b]喹啉化合物及其制备方法 |
FR2958290B1 (fr) | 2010-03-30 | 2012-10-19 | Sanofi Aventis | Procede de preparation de derives de sulfonamido-benzofurane |
HUP1000330A2 (en) | 2010-06-18 | 2011-12-28 | Sanofi Sa | Process for the preparation of dronedarone and the novel intermediates |
FR2963006B1 (fr) * | 2010-07-21 | 2013-03-15 | Sanofi Aventis | Procede de preparation de derives de nitro-benzofurane |
HUP1100167A2 (en) | 2011-03-29 | 2012-11-28 | Sanofi Sa | Process for preparation of dronedarone by mesylation |
HUP1100165A2 (en) | 2011-03-29 | 2012-12-28 | Sanofi Sa | Process for preparation of dronedarone by n-butylation |
CN103929963A (zh) | 2011-09-14 | 2014-07-16 | 萨穆梅德有限公司 | 吲唑-3-羧酰胺及其作为WNT/β-CATENIN信号传导通路抑制剂的用途 |
FR2983198B1 (fr) | 2011-11-29 | 2013-11-15 | Sanofi Sa | Procede de preparation de derives de 5-amino-benzoyl-benzofurane |
EP2617718A1 (de) | 2012-01-20 | 2013-07-24 | Sanofi | Verfahren zur Herstellung von Dronedaron unter Verwendung von Dibutylaminopropanolreagenz |
WO2013121235A2 (en) | 2012-02-13 | 2013-08-22 | Sanofi | Process for preparation of dronedarone by removal of hydroxyl group |
WO2013121234A1 (en) | 2012-02-14 | 2013-08-22 | Sanofi | Process for the preparation of dronedarone by oxidation of a sulphenyl group |
WO2013124745A1 (en) | 2012-02-22 | 2013-08-29 | Sanofi | Process for preparation of dronedarone by oxidation of a hydroxyl group |
PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
WO2013178337A1 (en) | 2012-05-31 | 2013-12-05 | Sanofi | Process for preparation of dronedarone by grignard reaction |
CN105120862A (zh) | 2013-01-08 | 2015-12-02 | 萨穆梅德有限公司 | Wnt信号途径的3-(苯并咪唑-2-基)-吲唑抑制剂及其治疗应用 |
WO2015032800A2 (en) * | 2013-09-03 | 2015-03-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for inducing senescence in cancer cells |
WO2016040185A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof |
WO2016040180A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
WO2016040193A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof |
WO2016040190A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof |
WO2016040181A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
WO2016040184A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
US10231956B2 (en) | 2015-08-03 | 2019-03-19 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
WO2017024010A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof |
WO2017023972A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
US10329309B2 (en) | 2015-08-03 | 2019-06-25 | Samumed, Llc | 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
WO2017023987A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof |
US10392383B2 (en) | 2015-08-03 | 2019-08-27 | Samumed, Llc | 3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
US10604512B2 (en) | 2015-08-03 | 2020-03-31 | Samumed, Llc | 3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof |
WO2017023988A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
US10206908B2 (en) | 2015-08-03 | 2019-02-19 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
US10285982B2 (en) | 2015-08-03 | 2019-05-14 | Samumed, Llc | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
US10206909B2 (en) | 2015-08-03 | 2019-02-19 | Samumed, Llc | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
WO2017024025A1 (en) | 2015-08-03 | 2017-02-09 | Sunil Kumar Kc | 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
WO2017024021A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof |
WO2017023975A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof |
US10285983B2 (en) | 2015-08-03 | 2019-05-14 | Samumed, Llc | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof |
US10226453B2 (en) | 2015-08-03 | 2019-03-12 | Samumed, Llc | 3-(1H-indol-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
US10166218B2 (en) | 2015-08-03 | 2019-01-01 | Samumed, Llc | 3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
EP3370721A4 (de) | 2015-11-06 | 2019-05-22 | Samumed, LLC | Behandlung von osteoarthritis |
HUE060797T2 (hu) | 2016-06-01 | 2023-04-28 | Biosplice Therapeutics Inc | Eljárás N-(5-(3-(7-(3-fluorfenil)-3H-imidazo[4,5-c]piridin-2-il)-1H-indazol-5-il)- piridin-3-il)-3-metilbutánamid elõállítására |
EP3528808B1 (de) | 2016-10-21 | 2021-10-06 | BioSplice Therapeutics, Inc. | Verfahren zur verwendung von indazol-3-carboxamiden und deren verwendung als hemmer des wnt/b-catenin-signalwegs |
WO2018085865A1 (en) | 2016-11-07 | 2018-05-11 | Samumed, Llc | Single-dose, ready-to-use injectable formulations |
RU2642924C1 (ru) * | 2017-03-13 | 2018-01-30 | Федеральное государственное бюджетное учреждение науки Институт органического синтеза им. И.Я. Постовского Уральского отделения Российской академии наук (ИОС УрО РАН) | Способ получения 5-фенил-3-(трифторметил)-1н-пиразол-4-амина |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8600752D0 (en) * | 1986-01-14 | 1986-02-19 | Roussel Lab Ltd | Chemical compounds |
US4748246A (en) * | 1987-05-07 | 1988-05-31 | American Home Products Corporation | Pyrazolo(4,3-c)quinolines |
MXPA04002682A (es) * | 2001-09-19 | 2004-06-18 | Pharmacia Corp | Compuestos pirazolilo sustituidos para el tratamiento de la inflamacion. |
-
2003
- 2003-07-03 AU AU2003304380A patent/AU2003304380A1/en not_active Abandoned
- 2003-07-03 CN CNA038267330A patent/CN1802373A/zh active Pending
- 2003-07-03 DE DE60319158T patent/DE60319158T2/de not_active Expired - Fee Related
- 2003-07-03 AT AT03742433T patent/ATE386034T1/de not_active IP Right Cessation
- 2003-07-03 JP JP2005507449A patent/JP2007521227A/ja active Pending
- 2003-07-03 BR BRPI0318383-1A patent/BR0318383A/pt not_active IP Right Cessation
- 2003-07-03 MX MXPA05013485A patent/MXPA05013485A/es unknown
- 2003-07-03 WO PCT/US2003/021144 patent/WO2005012301A1/en active IP Right Grant
- 2003-07-03 EP EP03742433A patent/EP1644371B1/de not_active Expired - Lifetime
- 2003-07-03 CA CA002531291A patent/CA2531291A1/en not_active Abandoned
-
2006
- 2006-01-02 IL IL172942A patent/IL172942A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
DE60319158D1 (de) | 2008-03-27 |
DE60319158T2 (de) | 2009-02-05 |
CA2531291A1 (en) | 2005-02-10 |
EP1644371A1 (de) | 2006-04-12 |
MXPA05013485A (es) | 2006-04-05 |
JP2007521227A (ja) | 2007-08-02 |
IL172942A0 (en) | 2006-06-11 |
BR0318383A (pt) | 2006-07-25 |
CN1802373A (zh) | 2006-07-12 |
AU2003304380A1 (en) | 2005-02-15 |
WO2005012301A1 (en) | 2005-02-10 |
EP1644371B1 (de) | 2008-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE386034T1 (de) | Pyrazoloisoquinolinenderivaten als kinase inhibitoren | |
RS20050363A (en) | Chk-,pdk-and akt-inhibitory pyrimidines,their production an use as pharmaceutical agents | |
CY1116754T1 (el) | Παραγωγα νιτροκατεχολης ως αναστολεις της comt | |
DE60309848D1 (de) | Purinderivate als kinaseinhibitoren | |
MY140074A (en) | INDOLE DERIVATIVES OR BENZIMIDAZOLE DERIVATIVES FOR MODULATING IkB KINASE | |
NO20070514L (no) | Pyrrolotriazin kinase inhibitorer | |
ATE304017T1 (de) | Oxazolylpyrazol-derivate als kinase-inhibitoren | |
EA201171454A1 (ru) | N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ | |
TNSN07027A1 (en) | Pyrrolo-pyridine kinase modulators | |
ATE411022T1 (de) | Pyridylpyrrol-derivate als wirksame kinase-hemmer | |
ATE408601T1 (de) | Fredericamycin-derivate | |
MXPA05010711A (es) | Compuestos y composiciones novedosos como inhibidores de proteina-quinasa. | |
EA200970738A1 (ru) | Ингибиторы активности akt | |
ATE300529T1 (de) | Imidazolderivate als raf-kinase-inhibitoren | |
DE60314603D1 (de) | Zusammensetzungen brauchbar als protein-kinase- inhibitoren | |
NO20083427L (no) | Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse | |
NO20082414L (no) | Inhibitorer av AKT-aktivitet | |
EA200801372A1 (ru) | Способы получения замещенных пиримидинов | |
EA200501928A1 (ru) | Пирролодигидроизохинолины как ингибиторы pde10 | |
ATE532789T1 (de) | Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren | |
ATE493418T1 (de) | Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren | |
DK1423384T3 (da) | Pyridinderivater som Raf kinaseinhibitorer | |
NO20073113L (no) | Indenylderivater og anvendelse derav for behandling av neurologiske lidelser | |
DE60214019D1 (de) | Stickstoff enthaltende heterozyklen und ihre verwendung als raf inhibitoren | |
ATE373658T1 (de) | Pyrazoloisoquinolinenderivaten zur inhibierung von nfkappab-induzierende kinase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |